Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
Moore JL, Green M, Santaolalla A, Deere H, Evans RPT, Elshafie M, Lavery A, McManus DT, McGuigan A, Douglas R, Horne J, Walker R, Mir H, Terlizzo M, Kamarajah SK, Van Hemelrijck M, Maisey N, Sita-Lumsden A, Ngan S, Kelly M, Baker CR, Kumar S, Lagergren J, Allum WH, Gossage JA, Griffiths EA, Grabsch HI, Turkington RC, Underwood TJ, Smyth EC, Fitzgerald RC, Cunningham D, Davies AR; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study group, The Guy's and St Thomas' Oesophago-gastric Research Group, and The PROGRESS study group. Moore JL, et al. Among authors: ngan s. J Clin Oncol. 2023 Oct 1;41(28):4522-4534. doi: 10.1200/JCO.23.00139. Epub 2023 Jul 27. J Clin Oncol. 2023. PMID: 37499209
Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL, Subesinghe M, Santaolalla A, Green M, Deere H, Van Hemelrijck M, Lagergren J, Chicklore S, Maisey N, Gossage JA, Kelly M, Baker CR, Davies AR; Guy’s and St Thomas’ Oesophago-gastric Research Group. Moore JL, et al. Eur Radiol. 2023 May;33(5):3647-3659. doi: 10.1007/s00330-023-09482-7. Epub 2023 Mar 15. Eur Radiol. 2023. PMID: 36920518 Free PMC article.
Association of dynamic contrast-enhanced MRI and 18F-Fluorodeoxyglucose PET/CT parameters with neoadjuvant therapy response and survival in esophagogastric cancer.
Withey SJ, Owczarczyk K, Grzeda MT, Yip C, Deere H, Green M, Maisey N, Davies AR, Cook GJ, Goh V; Guy's & St Thomas' Esophagogastric Research Group. Withey SJ, et al. Eur J Surg Oncol. 2023 Oct;49(10):106934. doi: 10.1016/j.ejso.2023.05.009. Epub 2023 May 10. Eur J Surg Oncol. 2023. PMID: 37183047 Free PMC article.
Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas.
Yu KK, Yeo A, Ngan S, Chu J, Chang D, Siva S, Wong A, Kron T, Hardcastle N, Gaudreault M, Chesson T, Williams S, Burns M, Chander S. Yu KK, et al. Among authors: ngan s. Radiother Oncol. 2024 Apr 21:110275. doi: 10.1016/j.radonc.2024.110275. Online ahead of print. Radiother Oncol. 2024. PMID: 38653378 No abstract available.
Immunotherapy targeting isoDGR-protein damage extends lifespan in a mouse model of protein deamidation.
Kalailingam P, Mohd-Kahliab KH, Ngan SC, Iyappan R, Melekh E, Lu T, Zien GW, Sharma B, Guo T, MacNeil AJ, MacPherson RE, Tsiani EL, O'Leary DD, Lim KL, Su IH, Gao YG, Richards AM, Kalaria RN, Chen CP, McCarthy NE, Sze SK. Kalailingam P, et al. Among authors: ngan sc. EMBO Mol Med. 2023 Dec 7;15(12):e18526. doi: 10.15252/emmm.202318526. Epub 2023 Nov 16. EMBO Mol Med. 2023. PMID: 37971164 Free PMC article.
169 results